Japan's aging population and persistent bacterial infection burden are keeping antibiotics a clinical staple, even as resistance concerns push the industry toward next-generation mechanisms. For a healthcare system built around universal coverage and an unusually old population, reliable antibiotic supply is less a growth story than a public-health necessity. According to Polaris Market...